Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Carestream’s Preclinical in Vivo Imaging Business to Be Acquired by Bruker

By BiotechDaily International staff writers
Posted on 05 Oct 2012
ADVERTISEMENT
SARTORIUS AG
Carestream Health (Rochester, NY, USA) and Bruker Corp. (Billerica, MA, USA) have entered into an agreement for Bruker to purchase the preclinical in vivo imaging equipment product range and related assets from Carestream’s molecular imaging business. Financial terms of the agreement are not being disclosed.

Carestream will retain the remaining assets of its molecular imaging business, including its life science X-ray film product lines and its Gel Logic and Image Station in vitro imaging equipment-product range. Carestream will continue operating its life science X-ray film business, and will continue to support its in vitro product customers with service and parts. New production of its Gel Logic and Image Station in vitro products will be discontinued.

Dr. Werner Maas, president of Bruker BioSpin Corp., commented, “We are excited about adding Carestream’s in vivo imaging systems to our preclinical imaging product portfolio. We believe that Carestream’s optical molecular imaging product line will complement our other preclinical solutions, presently consisting of magnetic resonance imaging [MRI], magnetic particle imaging [MPI] and X-ray micro computed tomography [microCT]. We also welcome the talented Carestream in vivo employees to Bruker, and look forward to their contributions.”

Carestream Health is a worldwide provider of dental and medical imaging systems and healthcare information technology (IT) solutions; X-ray film and digital X-ray systems for nondestructive testing; and sophisticated materials for the precision films and electronics markets.

Bruker Corp. is a provider of scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

Related Links:
Carestream Health
Bruker



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.